BioWorld A closer look BioWorld Asia BioWorld Science

BioWorld

Dwarfism golden gate? Bridgebio’s infigratinib phase III hits
Bridgebio Pharma Inc. kept the phase III wins coming, this time with positive top-line results from Propel 3, the global phase III pivotal study of oral infigratinib,...

More in BioWorld

A closer look

Cancer index surges 72% as Terns, Olema lead gains
The BioWorld Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow Jones Industrial Average (up 12.97%). The year...

More in A closer look

BioWorld Science

Tumor, immune and neural cells are involved in cancer cachexia
A circuit formed by tumor, immune and nervous systems triggers cancer cachexia and anorexia, the excessive loss of weight, muscle and fat experienced in some cancer types....

More in BioWorld Science

BioWorld Asia

Innovent-Lilly $8.5B deal signals new China inflection point
The scale of the $8.5 billion deal signed between Innovent Biologics Inc. and Eli Lilly and Co. is eye-catching, but the structure is the real signal. By shifting phase II...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.